Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
AskAt Inc
Domain Therapeutics SA
Eisai Co Ltd
Exalys Therapeutics Inc
GlaxoSmithKline Plc
Gurus BioPharm
Kaken Pharmaceutical Co Ltd
Kaph Therapeutics Inc
Medibiofarma SL
Mesentech Inc
NB Health Laboratory Co Ltd
Ono Pharmaceutical Co Ltd
RaQualia Pharma Inc
Rottapharm Biotech Srl
Shanghai Bioray Laboratory Inc
Sosei Group Corp
TempestTx, Inc.
Teon Therapeutics Inc
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
AAT-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BYD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-6086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize EP4 for Delirium and NeuroInflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-095895 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
grapiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-726701A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GUR-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAG-308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KNP-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBF-251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MES-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MES-1088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4578 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palupiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize EP4 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Prostanoid EP4 Receptor for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPST-1495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-038 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
Featured News & Press Releases
Aug 24, 2020: Adlai Nortye announces first patient dosed in phase 1b clinical trial of AN0025 (EP4 Antagonist) in combition with Merck’s KEYTRUDA (pembrolizumab) for advanced solid tumors
Jan 30, 2020: Tempest Therapeutics announces FDA clearance of investigatiol new drug application for TPST-1495 and welcomes new investors
Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
Jul 19, 2018: Investigatiol New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in Chi
Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
Jan 22, 2018: Investigatiol New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in Chi
Jan 22, 2018: Investigatiol New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in Chi
Dec 18, 2017: Investigatiol new drug application for EP4 antagonist AAT-007 was approved by the tiol Food and Drug Administration of the People’s Republic of Chi
Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea
Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress
Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress
Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)
Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AskAt Inc, 2021
Pipeline by Domain Therapeutics SA, 2021
Pipeline by Eisai Co Ltd, 2021
Pipeline by Exalys Therapeutics Inc, 2021
Pipeline by GlaxoSmithKline Plc, 2021
Pipeline by Gurus BioPharm, 2021
Pipeline by Kaken Pharmaceutical Co Ltd, 2021
Pipeline by Kanaph Therapeutics Inc, 2021
Pipeline by Medibiofarma SL, 2021
Pipeline by Mesentech Inc, 2021
Pipeline by NB Health Laboratory Co Ltd, 2021
Pipeline by Ono Pharmaceutical Co Ltd, 2021
Pipeline by RaQualia Pharma Inc, 2021
Pipeline by Rottapharm Biotech Srl, 2021
Pipeline by Shanghai Bioray Laboratory Inc, 2021
Pipeline by Sosei Group Corp, 2021
Pipeline by TempestTx, Inc., 2021
Pipeline by Teon Therapeutics Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)